Marketresearchnews

Thursday, 11 February 2021

Worldwide Cell Culture Media Market 2020 Outlook, Top 10 Industry Players Comprehensive Analysis And Forecast To 2023

The Global Cell Culture Media Market is expected to register a CAGR of 6.9% and is projected to reach USD 2,070.71 million by 2023. A cell culture media is a growth media designed to support the growth of cells. A cell culture media is composed of the appropriate composition of amino acids, vitamins, inorganic salts, glucose, serum, etc. It may require additional supplementary reagents and sera such as growth factors, hormones, lipids, trace elements, and minerals which are necessary for cell cultures to grow and survive in their incubation environment.

Browse Sample of the Report @ https://www.marketresearchfuture.com/sample_request/4462

The cell culture media market is driven by the growing pharmaceutical industry, rising biopharmaceutical drugs in the pipeline, increasing prevalence of cancer and infectious diseases, and increasing geriatric population. However, the cost of cell culture media and contamination of media are a threat to the growth of the market.

Market Dynamics

Rising research and development in the pharmaceutical and biotechnology industry is driving the growth of the cell culture media market. For instance, according to a recent survey, the pharmaceutical and biotechnology industry in the US spent a total of USD 102 billion on research and development in 2015. Additionally, according to the National Institute for Health Research, the Association of the British Pharmaceutical Industry (ABPI) invested over Euro 4.1 billion in 2015 just in the UK on R&D, looking for breakthroughs for conditions such as cancer, dementia, and rare genetic diseases. This growing research and development in the field of healthcare are leading to an upward demand for cell culture media.

Segmentation

The global cell culture media market has been segmented into product type, application, and end user. By product type, the market has been segregated into reagents, media, and sera. Based on media, the market has been divided into classical media, stem cell media, serum-free media, and others. The market, based on stem cell media, is further categorized as bone marrow, neural stem cells (NSCs), mesenchymal stem cells (MSCs), and embryonic stem cells (ESCs).

Based on application, the market has been bifurcated into biopharmaceutical, tissue-culture and manufacturing, gene therapy, cytogenetic, and others. By end user, the market has been classified as biopharmaceutical companies, academic and research laboratories, hospitals and diagnostics centers, and others.

Key Players

The major players in the global cell culture media market are Merck KGaA (Germany), Bio-Rad Laboratories, Inc. (US), Thermo Fisher Scientific Inc. (US), Lonza (Switzerland), GE Healthcare (US), Becton, Dickinson and Company (US), HiMedia Laboratories (India), Corning Incorporated (US), PromoCell (Germany), Sera Scandia A/S (Denmark), The Sartorius Group (Germany), and Fujifilm Holdings Corporation (Japan).

Some of the key strategies followed by the players operating in the global cell culture media market were mergers, acquisitions, and new product launches.

Browse More Details of the Report @ https://www.marketresearchfuture.com/reports/cell-culture-media-market-4462

About Us:

Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.

Contact Us:

Market Research Future

Office No. 528, Amanora Chambers

Magarpatta Road, Hadapsar,

Pune – 411028

Maharashtra, India

Phone: +1 646 845 9312

Email: sales@marketresearchfuture.com

Global Drug Discovery Informatics Market By Major Industry Trends And Forecast Business Opportunities And Threats In The Next 5 Years

Global drug discovery informatics market is expected to register a healthy CAGR over the forecast period. The market held a market value of USD 1,680.6 million in 2017 and is projected to grow at a CAGR of 11.5% during the forecast period. Drug discovery and development is a highly intricate process requiring the generation of very large amounts of data and information. Large amounts of data are generated using a variety of innovative technologies, and the limiting step is accessing, searching and integrating this data. The current approaches to collect information from various sources have been dealt with in some cases where the data types are very least well-defined or largely homogeneous. However, the world is on the verge of a new age of drug discovery informatics, the methods and approaches in which are dealing with gathering information from data and knowledge from information are undergoing a paradigm shift. Mining and integration of domain-specific information such as chemical and genomic data will continue to develop in the near future.

Browse Sample of the Report @ https://www.marketresearchfuture.com/sample_request/7831

Drug discovery is a functional process in pharmaceutical and biotechnology companies. It involves different steps and procedures that depend on in-silico tools for reducing the complexity of a process. Some of the factors driving the market growth are a rising worldwide focus on drug discovery, growing need to control drug discovery and development costs, growth in R&D expenditure, and increasing burden of chronic diseases. For instance, according to the World Health Organization (WHO), in 2001, chronic diseases contributed around 60% of the 56.5 million total reported deaths across the world and approximately 46% of the global burden of disease, which is projected that, by 2020, chronic diseases will account for almost three-quarters of all deaths worldwide. On the other hand, high pricing and setup cost of informatics software is anticipated to restrict the market growth during the forecast period.

Segmentation

The global drug discovery informatics market has been segmented into product, mode, service, end user, and region.

By product, the market has been segmented into discovery informatics and development informatics.

On the basis of mode, the market has been divided into in-house informatics and outsourced informatics.

By service, the market has been classified into sequencing and target data analysis, docking, molecular modeling, clinical trial data management, and others. The sequencing and target data analysis segment is expected to dominate the market over the forecast period due to rising application of informatics solutions in targeted analysis and a large amount of data generated during the drug discovery process.

Based on end user, the market has been categorized into pharmaceutical and biotechnology industries, contract research organizations (CROs), and others.

The global drug discovery informatics market has been segmented by region into the Americas, Europe, Asia-Pacific, and the Middle East & Africa. The drug discovery informatics market in the Americas has further been segmented into North America and Latin America, with the North American market divided into the US and Canada.

The European drug discovery informatics market has been segmented into Western Europe and Eastern Europe. The Western Europe drug discovery informatics market has further been classified as Germany, France, the UK, Italy, Spain, and the rest of Western Europe.

The drug discovery informatics market in Asia-Pacific has been segmented into Japan, China, India, South Korea, Australia, and the rest of Asia-Pacific. The drug discovery informatics market in the Middle East & Africa has been segmented into the Middle East and Africa.

Key players

Few of the spearheads in the global drug discovery informatics market are Thermo Fisher Scientific, Inc., PerkinElmer, Inc., Certara, L.P., Infosys Limited, Novo Informatics Pvt. Ltd., Collaborative Drug Discovery Inc., Selvita, Charles River Laboratories, Inc., International Business Machines Corporation, Jubilant Life Sciences Ltd., IO Informatics, Inc., GVK Biosciences Private Limited, and Dassault Systèmes.

Browse More Details of the Report @ https://www.marketresearchfuture.com/reports/drug-discovery-informatics-market-7831

About US:

Contact Us:

Market Research Future

Office No. 528, Amanora Chambers

Magarpatta Road, Hadapsar,

Pune – 411028

Maharashtra, India

Phone: +1 646 845 9312

Email: sales@marketresearchfuture.com

Global Healthcare Information Systems Market Production, Capacity, Revenue, Price, Gross Margin Analysis And Forecast 2020-2023

The global healthcare information systems market is expected to register a CAGR of 10.0% during the forecast period of 2018 to 2023.

Healthcare information technology offers solutions for security and data management of information related with healthcare. Currently, information technology has more effect on the cost quality and safety associated with healthcare. Some commonly used applications in the healthcare industry include electronic medical records, healthcare records and personal health records.

Browse Sample of the Report @ https://www.marketresearchfuture.com/sample_request/7325

Healthcare Information Systems Market Segmentation

The global healthcare information systems market is segmented based on type, components, deployment, end user, and region.

On the basis of type, the market is segmented into hospital information systems, pharmacy information systems, laboratory information systems, medical imaging information system, revenue cycle management. The hospital information systems segment is sub-segmented into electronic health record, electronic medical record, real-time healthcare, patient engagement solutions, population health management and others. The pharmacy information systems segment is sub-segmented into prescription management, automated dispensing systems, inventory management and others. The medical imaging information System is sub-segmented into radiology information systems, monitoring analysis software, picture archiving & communication systems and others. Based on components, the market is divided into two, i.e., Software and Hardware. Based on deployment, the market is divided into web-based, on premise and cloud-based. By end user, the market is divided into hospitals, diagnostics centre, academic and research institution, and others. In the current scope of the study, the above-mentioned segments are covered into four global regions, namely- the Americas, Europe, Asia Pacific and the Middle East & Africa.

Healthcare Information Systems Regional Market Summary

The Americas dominated the global market of healthcare information systems. Rising demand for high quality diagnostics system is the main reason behind the supremacy of the North America’s healthcare information system market. Furthermore, large-scale implementation and storage of electronic records in the healthcare system witnessed in the countries such as Canada and the U.S is supporting the expansion of this regional healthcare information system market.

In 2017, it was estimated that Europe stood second in the global healthcare information systems market. This can be attributed due to the presence of a well-developed healthcare infrastructure, increasing awareness for the condition and presence of developed economies within the region.

Asia Pacific was the fastest growing region for the global healthcare information systems market in 2017. Asia-Pacific has a huge market potential for Healthcare IT industry. India and China are some of the rapidly growing countries, followed by South Korea. Consequently, the government in these rapidly developing economies have taken various efforts to improve healthcare services and provide better infrastructure.

On the other hand, the Middle East and Africa held least share in the global healthcare information systems market. Presence of poor economies and low per capita income, especially within the African region make the market to lag within the region. Most of the market share within this region is estimated to be held by the Middle East due to increasing government funding in the healthcare, and presence of developed economies like UAE, Kuwait, Dubai, and others.

Browse More Details of the Report @ https://www.marketresearchfuture.com/reports/healthcare-information-systems-market-7325

About US:

Contact Us:

Market Research Future

Office No. 528, Amanora Chambers

Magarpatta Road, Hadapsar,

Pune – 411028

Maharashtra, India

Phone: +1 646 845 9312

Email: sales@marketresearchfuture.com

Worldwide Radiofrequency Ablation Devices Market 2020 Outlook, Top 10 Industry Players Comprehensive Analysis And Forecast To 2023

The global radiofrequency ablation devices market is expected to register a CAGR of 11.2% during the forecast period of 2018 to 2023.

Radiofrequency ablation (RFA) uses thermal energy to achieve targeted tissue destruction. Within the GI tract, Radiofrequency ablation was primarily studied for the treatment of dysplastic Barrett’s esophagus (BE), and this continues to be one of the common applications. Indications for Radiofrequency ablation within the GI tract continue to progress. It has been used in the treatment of esophageal squamous cell dysplasia, cholangiocarcinoma, radiation proctopathy, gastric antral vascular ectasia (GAVE), and pancreatic neoplasia, among other conditions.

Browse Sample of the Report @ https://www.marketresearchfuture.com/sample_request/7634

Radiofrequency ablation devices use an electrosurgical generator connected to bipolar electrode arrays to deliver thermal energy to tissue. Electricity travels through tissue between alternating positive and negative poles along the electrode arrays of the radiofrequency ablation device in the radiofrequency range of 450 to 500 kHz.

Segmentation

The global radiofrequency ablation devices market is segmented on the basis of type, application, and region.

On the basis of the type, the global radiofrequency ablation devices market is segmented into Unipolar radiofrequency ablation and Bipolar radiofrequency ablation. By application, the global radiofrequency ablation devices market is categorized into Surgical Oncology, Cardiology and Cardiac Rhythm Management, Gynecology, Cosmetology, Pain Management

Key players

Some of the key players in the global radiofrequency ablation devices market are Boston scientific corporation, Medtronic Inc, Stryker, Cosman Medical, Inc., St. Jude Medical, Smith & Nephew, Johnson & Johnson (J&J) Services, LLC, Angiodynamics, RF Medical Co, Ltd, AtriCure, Inc., and others

Regional Market

The Americas dominates the global market for radiofrequency ablation devices owing a growing number of lung cancer cases like, Non-Small Cell Lung Cancer (NSCLC) which is the most common type of lung cancer, accounting for 80-85% of all lung cancer cases. It is generally a slow growing and spreading as compared to small cell lung cancer (SCLC). Small cell lung cancer used to account for 12-13% of lung cancers. However, there has been a shift from NSCLC to SCLC in recent years which has propelled the growth of the radiofrequency ablation devices market.

In 2017, it was estimated that Europe stood second in the global radiofrequency ablation devices market.

Asia-Pacific was the fastest growing region for the global radiofrequency ablation devices market in 2017. Factors such as increasing awareness of the cardiac disease, growing healthcare industries, and the development of various treatment methods for gynecology and cosmetology drives the market in this region.

On the other hand, the Middle East and Africa holds the least share in the global radiofrequency ablation devices market. The presence of poor economies and low per capita income, especially within the African region make the market to lag within the region. A majority of the market share within this region is estimated to be held by the Middle East due to increasing government funding in the healthcare for healthcare, and presence of developed economies like UAE, Kuwait, Dubai, and others.

Browse More Details of the Report @ https://www.marketresearchfuture.com/reports/radiofrequency-ablation-devices-market-7634

About US:

Contact Us:

Market Research Future

Office No. 528, Amanora Chambers

Magarpatta Road, Hadapsar,

Pune – 411028

Maharashtra, India

Phone: +1 646 845 9312

Email: sales@marketresearchfuture.com

Global Q fever Market Production, Capacity, Revenue, Price, Gross Margin Analysis And Forecast 2020-2023

The Global Q fever market is expected to grow at CAGR of 7.83% to reach USD 6,249.68 thousand till 2023. Some of the protuberant drivers supporting the growth of the global Q fever market are identified as growth in the prevalence of chronic diseases and the increasing number of patients suffering from various bacterial infections.

The rising prevalence of Q fever coupled with increasing Q fever hospitalization rates, rising worldwide cattle, sheep, and goat population, growth in the risk factors of Q fever, and globally growing geriatric population are expected to drive the global Q fever market in coming years.

Browse Sample of the Report @ https://www.marketresearchfuture.com/sample_request/5490

Segmentation

Global Q fever, by type, segmented into acute and chronic. Chronic is the leading segment, which is growing at the highest CAGR to reach USD 706.20 thousand by the end of 2023. Chronic Q fever is a life threating problem and causes damage to the heart, lungs, liver, brain, and could cause diabetes as well. The major share of the chronic segment is attributed to its high prevalence.

Based on diagnosis, Q fever market is segmented into serology tests and others. The serology tests account for major share with 8.32% CAGR during the forecast period. Under the serology test, Q fever is diagnosed through antibody blood tests, polymerase chain reaction (PCR) tests, immunoperoxidase staining, complement fixation, enzyme-linked immunosorbent assay (ELISA) tests, and other molecular tests.

The Q fever market, by treatment, is segmented into antibiotic and surgery. The antibiotics segment accounts for the second largest share in the market with 7.32% CAGR during the forecast period. Surgery is an important component of treatment if patients have extensive valvular damage or indications of heart failure.

On the basis of end user, the market is segmented into patients, hospitals and clinics, and others. The patient segment accounted for a considerable market share of 72.1% as of 2017.

Regional Analysis

The Asia-Pacific accounted for the largest market share of 44.5% as of 2017 and is projected to grow at the highest CAGR of 8.57% during the forecast period. The increasing prevalence of chronic diseases such as diabetes, cancer, and bacterial infection in developing countries is the major driver for market growth. According to the International Diabetic Federation, about 415 million people had diabetes across the globe in 2015, which is expected to reach 642 million by 2040. It also stated that 98.4 million and 65.1 million diabetic population lived in China and India, respectively.

The Asia-Pacific is followed by Europe, which accounted for a major market share. The European market is expected to grow at a strong growth rate during the forecast period owing to the availability of advanced treatment facilities and healthcare expenditure along with growing pet adoption.

The Americas accounted for a significant share in the global Q fever market. It is attributed to the increasing adoption of pets, increasing preventive treatments, and care facilities for companion animals, rising technically advanced devices, and growing awareness regarding animal-transmitted diseases.

Key Players

The prominent players in the global Q fever market are Merck KGaA (Germany), Teva Pharmaceutical (Israel), Pfizer Inc. (US), Basilea Pharmaceutica Ltd (Switzerland), Sanofi S.A.(France), Melinta Therapeutics, Inc. (US), Bayer AG (Germany), Johnson & Johnson Services, Inc. (US), Yashica Pharmaceuticals (India), AtoxBio (US), and others.

Browse More Details of the Report @ https://www.marketresearchfuture.com/reports/q-fever-market-5490

About US:

Contact Us:

Market Research Future

Office No. 528, Amanora Chambers

Magarpatta Road, Hadapsar,

Pune – 411028

Maharashtra, India

Phone: +1 646 845 9312

Email: sales@marketresearchfuture.com

Hemostasis and Tissue Sealing Agents Market Revenue, Opportunity, Forecast And Value Chain Analysis 2023

Global hemostasis and tissue sealing agents market is expected to grow significantly and is projected to grow at a CAGR of 8.6% over the forecast period. Hemostats, adhesives and sealants are useful aides to modern surgical procedures. Topical hemostats are utilized intraoperatively first and postoperatively to a reduce extent. These products can be utilized to diffuse raw surface bleeding, bone bleeding, oozing venous type bleeds, and needle-opening bleeding. There has been increasing demand for such products as it reduces complication during surgical procedures. Moreover, large number of surgical procedures across the globe are impacting the growth of the market positively. Surgical procedures are medical interventions involving an incision with instruments usually performed in an operating theatre and normally involving various medical devices such as catheters and tubes. For instance, according to the Center for Diseases Control and Prevention, approximately 46.5 million surgical procedures are performed every year in the U.S. Additionally, according to the NHS, surgery is the most important treatment offered by the NHS in secondary care within the UK. Furthermore, in 2015, NHS estimated that there were around 4.7 million surgical admissions in England, out of which 1.3 million procedures were for general surgery and around 1.2 million procedures were for trauma and orthopedics.

Browse Sample of the Report @ https://www.marketresearchfuture.com/sample_request/7559

These high surgical procedure numbers lead to rising need for hemostasis and tissue sealing agents which reduces the risk during surgical procedures. However, factors such as increasing advancement minimally invasive procedures, lack of reimbursement for these products is hampering the growth of the market.

Hemostasis and Tissue Sealing Agents Market Segmentation

The global hemostasis and tissue sealing agents market has been segmented into product, and end user.

By product, the market has been segmented into topical hemostats, and adhesive & tissue sealant. Furthermore, topical hemostats is divided into Active, mechanical (collagen based hemostats, cellulose based hemostats, gelatin based hemostats, polysaccharide based hemostats) Flowable. Adhesive & tissue sealant is further segmented into synthetic, natural, and adhesion barrier.

Further on the basis of end user the market is bifurcated into hospitals, ambulatory centers and others

The global Hemostasis and tissue sealing agents market has been segmented, by region, into the Americas, Europe, Asia-Pacific, and the Middle East & Africa. The diagnostics imaging workstations market in the Americas has further been segmented into North America and Latin America, with the North American market divided into the US and Canada.

The European Hemostasis and tissue sealing agents market has been segmented into Western Europe and Eastern Europe. The Western Europe diagnostics imaging workstations market has further been classified as Germany, France, the UK, Italy, Spain, and the rest of Western Europe.

The diagnostics imaging workstations market in Asia-Pacific has been segmented into Japan, China, India, South Korea, Australia, and the rest of Asia-Pacific. The diagnostics imaging services market in the Middle East & Africa has been segmented into the Middle East and Africa.

Hemostasis and Tissue Sealing Agents Market Key players

Johnson & Johnson, Cryolife, Inc., Baxter International, Inc, Ethicon LLC, Integra Lifesciences Corporation, Becton, Dickinson & Company, Cohera Medical, Inc., Pfizer, Inc, Medtronic plc, B. Braun Melsungen AG, MIL Laboratories Pvt. Ltd, Advanced Medical Solutions Group Plc

Hemostasis and Tissue Sealing Agents Regional Market Summary

Geographically, the Americas is anticipated to dominate the global hemostasis and tissue sealing agents market owing to the high clinical R&D budgets by both government as well as public and private organizations, presence of major manufacturers for the products, high number of surgical procedures and various others. Europe is expected to hold the second largest position in the global hemostasis and tissue sealing agents market. The Hemostasis and tissue sealing agents market in Asia-Pacific region consists of countries namely China, Japan, Republic of Korea, India, Australia and Rest of Asia-Pacific. The Asia-Pacific region is expected to be fastest growing region owing to increased medical tourism for surgical procedures, increasing healthcare expenditure in developing countries and various others. The Middle East & Africa has the lowest share of the global hemostasis and tissue sealing agents market. Majority of the market of the region is anticipated to be held by the Middle East region owing to the growing government initiatives for the healthcare sector.

Browse More Details of the Report @ https://www.marketresearchfuture.com/reports/hemostasis-tissue-sealing-agents-market-7559

About US:

Contact Us:

Market Research Future

Office No. 528, Amanora Chambers

Magarpatta Road, Hadapsar,

Pune – 411028

Maharashtra, India

Phone: +1 646 845 9312

Email: sales@marketresearchfuture.com

Transdermal (Percutaneous) Drug Delivery Systems Market Revenue, Opportunity, Forecast And Value Chain Analysis 2023

The global transdermal (percutaneous) drug delivery systems market is expected to register a healthy CAGR over the forecast period. The market held a market value of USD 5,400.2 million in 2017 and is projected to grow at a CAGR of 4.6% during the forecast period from 2018 to 2023. Transdermal drug delivery system (TDDS) delivers drugs through the skin to systemic circulation at a predetermined rate and maintain the effective concentrations clinically over an extended period. TDDS also called as patches are dosage forms that deliver a therapeutically effective amount of drug via the patients’ skin. Worldwide growing geriatric population along with rising in the prevalence of chronic diseases is the leading factor driving the market growth. In addition, rapid technological advancements in transdermal drug delivery systems and increasing adoption of third-generation delivery systems are expected to augment the market growth during the forecast period. The geriatric population is more prone to develop Q fever. The elderly population across the world is on the surge. The World Health Organization (WHO) reported that the worldwide population aged 60 years and above was 962.0 million in 2017, which is projected to increase to over 2.0 billion by 2050 and further would reach to 3.1 billion by 2100.

Browse Sample of the Report @ https://www.marketresearchfuture.com/sample_request/7545

However, disadvantages of delivery systems including edema and irritation, natural limits of drug entry imposed by the skin’s impermeability, and lack of adhesion of the transdermal system to different skin types are anticipated to hinder the market growth over the forecast period. Additionally, drugs that require high blood levels cannot be administered through TDDS as it is limited only to potent molecules, those requiring a daily dose of 10 mg or less, thereby affecting the market growth.

Transdermal Drug Delivery Systems Market Segmentation

The global transdermal (percutaneous) drug delivery systems market has been segmented into product, technology, application, and region.

By product, the market has been segmented into transdermal patches and transdermal semisolids. The transdermal patches segment is further categorized into drug-in-adhesive patches, matrix patches, reservoir membrane patches, and microneedle patches. The transdermal semisolids segment is additionally divided into gels, ointments, and sprays. The transdermal patches segment spearheaded the market in 2017 due to its benefits offered such as improved bioavailability, reduced dosing frequency, lower adverse events, enhanced patient compliance (non-invasive nature), painless application, and drug input termination at any point by the removal of the patch.

On the basis of technology, the market has been divided into electric current, iontophoresis, electroporation, ultrasound, microporation, thermal, and others.

Based on application, the market has been categorized into pain management, cardiovascular diseases, hormone replacement therapy, central nervous system disorders, smoking cessation, contraception, and others.

The global transdermal (percutaneous) drug delivery systems market has been segmented by region into the Americas, Europe, Asia-Pacific, and the Middle East & Africa. The transdermal (percutaneous) drug delivery systems market in the Americas has further been segmented into North America and Latin America, with the North American market divided into the US and Canada.

The European transdermal (percutaneous) drug delivery systems market has been segmented into Western Europe and Eastern Europe. The Western Europe transdermal (percutaneous) drug delivery systems market has further been classified as Germany, France, the UK, Italy, Spain, and the rest of Western Europe.

The transdermal (percutaneous) drug delivery systems market in Asia-Pacific has been segmented into Japan, China, India, South Korea, Australia, and the rest of Asia-Pacific. The transdermal (percutaneous) drug delivery systems market in the Middle East & Africa has been segmented into the Middle East and Africa.

Browse More Details of the Report @ https://www.marketresearchfuture.com/reports/transdermal-drug-delivery-systems-market-7545

About US:

Contact Us:

Market Research Future

Office No. 528, Amanora Chambers

Magarpatta Road, Hadapsar,

Pune – 411028

Maharashtra, India

Phone: +1 646 845 9312

Email: sales@marketresearchfuture.com